Stergios Tzikas1, Dennis Schlak2, Kateryna Sopova3, Aikaterini Gatsiou3, Dimitrios Stakos4, Kimon Stamatelopoulos5, Konstantinos Stellos6, Christoph Laske7. 1. Department of Cardiology, Ruhr University Bochum, Marienhospital Herne, Herne, Germany. 2. Department of Neurology, University of Tübingen, Tübingen, Germany. 3. Vascular Inflammation Group, Institute of Cardiovascular Regeneration, Centre of Molecular Medicine, J.W. Goethe University Frankfurt am Main, Frankfurt am Main, Germany. 4. Cardiology Clinic, Democritus University of Thrace, Alexandroupolis, Greece. 5. Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens, Greece. 6. Vascular Inflammation Group, Institute of Cardiovascular Regeneration, Centre of Molecular Medicine, J.W. Goethe University Frankfurt am Main, Frankfurt am Main, Germany Department of Cardiology, Centre of Internal Medicine III, J.W. Goethe University Frankfurt am Main, Frankfurt am Main, Germany. 7. Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany Section for Dementia Research, Hertie-Institute of Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany.
Abstract
BACKGROUND: Increasing evidence supports the role of cardiovascular risk factors in the development of Alzheimer's disease (AD). OBJECTIVE: In the present pilot study, we investigated plasma concentrations of myeloperoxidase (MPO) and its possible association with plasma amyloid-β (Aβ)1-42/1-40 ratio in AD patients and elderly healthy controls. METHODS: The study sample included 28 AD patients and 27 elderly individuals with a normal cognitive status as a control group. The Mini-Mental Status Examination was used to determine the global cognition. MPO, Aβ1-40, and Aβ1-42 plasma concentrations were measured by enzyme linked immunoabsorbent assays. RESULTS: AD patients showed significantly higher plasma concentrations of MPO in comparison to healthy elderly controls (AD versus healthy elderly controls (mean ± SD): 132.8 ± 114.8 ng/mL versus 55.0 ± 42.6 ng/mL; p = 0.002). MPO plasma concentrations showed a significant positive correlation in the whole sample with the presence of AD (ρ = 0.428, p < 0.001) and its stage (ρ = 0.331; p = 0.013) as well as with plasma concentrations of Aβ1-42 (ρ = 0.406; p = 0.004) and Aβ1-42/1-40 ratio (ρ = 0.354; p = 0.013). In a binary logistic regression model, plasma MPO concentrations were independently associated with the presence of AD (p = 0.014). CONCLUSION: AD patients showed significantly increased plasma levels of MPO, which could be an important molecular link between atherosclerosis and AD. Further studies should evaluate whether MPO may also be a useful biomarker and potential new treatment target in AD.
BACKGROUND: Increasing evidence supports the role of cardiovascular risk factors in the development of Alzheimer's disease (AD). OBJECTIVE: In the present pilot study, we investigated plasma concentrations of myeloperoxidase (MPO) and its possible association with plasma amyloid-β (Aβ)1-42/1-40 ratio in ADpatients and elderly healthy controls. METHODS: The study sample included 28 ADpatients and 27 elderly individuals with a normal cognitive status as a control group. The Mini-Mental Status Examination was used to determine the global cognition. MPO, Aβ1-40, and Aβ1-42 plasma concentrations were measured by enzyme linked immunoabsorbent assays. RESULTS:ADpatients showed significantly higher plasma concentrations of MPO in comparison to healthy elderly controls (AD versus healthy elderly controls (mean ± SD): 132.8 ± 114.8 ng/mL versus 55.0 ± 42.6 ng/mL; p = 0.002). MPO plasma concentrations showed a significant positive correlation in the whole sample with the presence of AD (ρ = 0.428, p < 0.001) and its stage (ρ = 0.331; p = 0.013) as well as with plasma concentrations of Aβ1-42 (ρ = 0.406; p = 0.004) and Aβ1-42/1-40 ratio (ρ = 0.354; p = 0.013). In a binary logistic regression model, plasma MPO concentrations were independently associated with the presence of AD (p = 0.014). CONCLUSION:ADpatients showed significantly increased plasma levels of MPO, which could be an important molecular link between atherosclerosis and AD. Further studies should evaluate whether MPO may also be a useful biomarker and potential new treatment target in AD.
Authors: Faten Shaeib; Sana N Khan; Iyad Ali; Tohid Najafi; Dhiman Maitra; Ibrahim Abdulhamid; Ghassan M Saed; Subramaniam Pennathur; Husam M Abu-Soud Journal: PLoS One Date: 2015-04-02 Impact factor: 3.240
Authors: Elles Douven; Syenna H J Schievink; Frans R J Verhey; Robert J van Oostenbrugge; Pauline Aalten; Julie Staals; Sebastian Köhler Journal: BMC Neurol Date: 2016-05-12 Impact factor: 2.474